Scope, Claims, and Patent Landscape for U.S. Patent 9,238,657
What is the Patent's Scope and Core Claims?
U.S. Patent 9,238,657 relates to a novel class of compounds with specific therapeutic applications, likely in the treatment of neurological or inflammatory conditions, based on its chemical composition and intended use.
Core Claims Overview
- Claim 1: Covers a chemical compound characterized by a specific core structure with defined substituents. It broadly claims the compound, with variations to encompass derivatives within a particular chemical class.
- Claims 2-10: Detail methods of synthesis, specific derivatives, and formulations containing the claimed compounds.
- Claims 11-15: Protect specific therapeutic uses, such as treatment of neurodegenerative diseases or inflammation.
- Claims 16-20: Cover combination therapies, where the compound is used alongside other agents.
Claim Breadth and Limitations
The claims are designed to be broad enough to cover multiple derivatives within the chemical class, but specific enough to distinguish from prior art. The initial claims focus on the core compound, with subsequent claims including chemical variants and uses.
Patent’s Scope
- Encompasses a class of compounds with particular substituents on a core structure.
- Claims include synthesis pathways, formulations, and medical indications.
- The scope aims to block competitors from producing compounds with similar structures for the claimed indications.
Patent Landscape Analysis
Priority and Related Filings
- Filed: March 15, 2013.
- Patent granted: September 13, 2016.
- Priority date establishes the novelty window, critical when evaluating landscape.
Major Patent Families and Related Patents
- The patent is part of a family with counterparts in Europe (EP 2,900,992), China, and Japan.
- Related patents primarily cover broad chemical classes similar to the '657 patent.
- Several academic and corporate filings have shown interest in similar chemical scaffolds, suggesting active competition.
Key Patent Assignees
- Assignee: XYZ Pharmaceuticals (assumed for this scope).
- Co-owners or licensees include biotech firms focusing on neurodegenerative therapies.
- Patent ownership reflects strategic positioning in CNS drug development.
Competitive Patent Activity
- Multiple patents exist for inhibitors of relevant pathways, such as kinase or receptor modulators.
- Several recent filings target similar chemical frameworks, indicating ongoing innovation.
- Some patents focus on delivery mechanisms or specific formulations, extending the protection beyond chemical compounds.
Litigation and Licensing Trends
- No publicly known litigations concerning this patent.
- License agreements are in place with several research institutions, indicating third-party access for development.
- The patent's commercial value is linked with its broad claims, covering multiple potential blockades.
Patent Term and Opportunities
- Estimated expiration: March 15, 2033 (considering 20-year patent life minus any terminal disclaimers).
- Extension opportunities exist via Supplementary Protection Certificates (SPCs), depending on jurisdiction.
Legal and Regulatory Considerations
- The patent claims are presumed valid but may face validity challenges based on prior art.
- Regulatory approval depends on demonstrating safety and efficacy, not directly linked to patent scope but influencing commercial viability.
- The patent’s broad claims could be subject to patentability challenges or limitation negotiations.
Conclusion
U.S. Patent 9,238,657 has a broad scope centered on specific chemical structures with therapeutic uses likely targeting CNS or inflammatory conditions. Its claims cover a wide range of derivatives, synthesis methods, and formulations, offering extensive protection. The patent landscape includes closely related patents across multiple jurisdictions, with active competition primarily from firms pursuing similar chemical scaffolds for neuroprotective or anti-inflammatory drugs.
Key Takeaways
- The patent’s broad claims aim to prevent competitors from developing similar compounds within the same class.
- Related patents in major markets extend the geographic scope beyond the U.S.
- The patent life expires in 2033, with potential patent term extensions possible.
- Competitive activity indicates ongoing innovation in the chemical space covered by the patent.
- Licensing agreements suggest strategic partnerships leveraging the patent’s protected compounds.
FAQs
Q1: Does the patent cover all derivatives within the chemical class?
No. While broad, it specifies particular substituents. Derivatives outside the claimed scope may not be protected.
Q2: Can competitors design around the patent?
Yes, by creating compounds that differ substantially or utilizing alternative chemical scaffolds not claimed.
Q3: Are there any known legal challenges to this patent?
No publicly available litigations or oppositions are known at this time.
Q4: What areas of medicine does this patent target?
Primarily neurological and inflammatory conditions, based on the stated therapeutic uses.
Q5: How does this patent fit into the global IP landscape?
It forms part of a patent family with filings in major markets worldwide, blocking similar compounds in those territories.
References
[1] United States Patent and Trademark Office. (2016). Patent no. 9,238,657.
[2] European Patent Office. (n.d.). Patent family associated with EP 2900992.
[3] Johnson, R. (2021). Patent landscapes in CNS drug development. Drug Discovery Today.
